Acutaas Chemicals Ltd
Acutaas Chemicals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
The company targets a 25% revenue growth for the full financial year FY '27. Company targets a 25% revenue growth for FY '27, confident to maintain similar EBITDA margins as FY '26 despite higher revenue.
From Acutaas Chemicals Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- The company targets a 25% revenue growth for the full financial year FY '27.
- Battery chemicals business expected to ramp up to full capacity utilization (4,000 MT) by FY '29, indicating strong volume growth.
- Semiconductor business (Indichem plant) to start contributing revenues from FY '28 and expected to reach full capacity within 3-4 years.
- Pharma Intermediates, including CDMO business, expected to grow strongly, with CDMO revenue target of INR 1,000 crores and confident to exceed it.
- Spec Chem business revenue mix to grow due to battery chemicals and new higher-margin specialty chemicals despite phasing out commodity chemicals.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Acutaas Chemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '27 capex estimated at around INR 90-95 crores, including:
- Spillover capex of electrolyte additives and pilot plant capex (~INR 50 crores)
- Maintenance capex of INR 40-45 crores
- Additional capex planned for a new R&D center and land acquisition for future capacity expansion; details to be announced when finalized.
- Land acquisition is intended to support capacity expansion for the Pharma Intermediate business as existing plants (Sachin and Ankleshwar) approach full utilization by FY '28.
- Indichem plant construction is ahead of schedule, with capex completion expected by end of Q1 FY '27; revenue anticipated from next financial year.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Acutaas Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Acutaas Chemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹433 Cr, net profit ₹134 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Acutaas Chemicals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
Frequently Asked Questions
What were Acutaas Chemicals Ltd Q1 FY27 results?
The company targets a 25% revenue growth for the full financial year FY '27. Company targets a 25% revenue growth for FY '27, confident to maintain similar EBITDA margins as FY '26 despite higher revenue.
What is Acutaas Chemicals Ltd share price analysis?
Acutaas Chemicals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 72.9 with a market cap of ₹28,166 Cr. Investors should review the full earnings analysis for detailed insights.
Is Acutaas Chemicals Ltd planning capital expenditure?
FY '27 capex estimated at around INR 90-95 crores, including: - Spillover capex of electrolyte additives and pilot plant capex (~INR 50 crores) - Maintenance capex of INR 40-45 crores - Additional capex planned for a new R&D center and land acquisition for future capacity expansion; details to be announced when finalized.
Keep Acutaas Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.